Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects
https://grants.nih.gov/grants/guide/notice-files/NOT-DA-21-028.html
march 25, 2021pa-20-185 - nih research project grant (parent r01 clinical trial not allowed)pa-20-195 - nih exploratory/developmental research grant program (parent r21 clinical trial not allowed)pa-20-200 - nih small research grant program (parent r03 clinical trial not allowed)national institute on drug abuse (nida)this notice informs potential applicants to the national institute on drug abuse (nida) about a special interest in research on chemistry, pharmacology, biological targets and biochemical mechanisms that contribute to the effects of synthetic psychoactive substances.backgroundsynthetic psychoactive drugs (spds) also known as designer drugs, new or novel psychoactive substances (nps) are compounds that are specifically designed to mimic the actions of known drugs. spds can be broadly classified as follows:1) synthetic cannabinoids (scs) and thc-mimics that produce experiences similar to marijuana; 2) synthetic stimulants and mimetics such as the cathinones, pyrovalerones, amphetamines and tryptamines; 3) synthetic opioids (opioid-mimics, fentanyl and fentanyl analogs); 4) serotonergic and atypical psychedelics that produce hallucinogenic and toxic effects; 5) benzodiazepines, gaba analogs; and 6) other spds, npss, and designer drugs such as those currently being used overseas and have potential for misuse in the us. in addition to their misuse potential, these synthetic psychoactive substances produce peripheral and central toxicity of varying severity. this toxicity is particularly concerning as use of these substances is on the rise. the surge of spd use during the last 8-10 years is a major public health concern and necessitates a broad research agenda to guide prevention and treatment strategies.there is a significant need for research aimed at investigating the receptor targets, signaling pathways, impact on circuits and neural networks and neurodevelopmental effects of spds. although little is known about their detailed pharmacology, toxicology and metabolism, some of the spds have shown potent activity at the monoamine neurotransmitter and endocannabinoid systems. there are reports showing that rats self-administer cathinones similar to, or more robustly than, methamphetamine. spds can also induce intense cravings, tolerance, physical dependence, and strong withdrawal symptoms. a number of toxicological symptoms have been reported with synthetic drugs although the mechanisms underlying the toxicity remains to be fully explored. further research is therefore needed to understand the mechanisms contributing to the toxicological profile of spds and to identify potential pharmacological approaches to treat spd intoxication.research objectivesthe goal of this notice is to encourage basic preclinical research to understand the chemistry, pharmacology, and molecular mechanisms of actions of the spds. areas of interest include, but are not limited to:application and submission informationthis notice applies to due dates on or after june 5, 2021 and subsequent receipt dates through september 7, 2024.submit applications for this initiative using one of the following funding opportunity announcements (foas) or any reissues of these announcement through the expiration date of this notice.all instructions in the sf424 (r&r) application guide and the funding opportunity announcement used for submission must be followed, with the following additions:applications nonresponsive to terms of this nosi will not be considered for the nosi initiative.scientific/research contact(s)sam ananthan, ph.d. national institute on drug abuse (nida) telephone: 301-435-2199 email: sam.ananthan@nih.govfinancial/grants management contact(s)pamela g. fleming national institute on drug abuse (nida) telephone: 301-480-1159 email: pfleming@nih.govweekly toc for this announcement nih funding opportunities and noticesnote: for help accessing pdf, rtf, ms word, excel, powerpoint, audio or video files, see help downloading files.